fluoxetine has been researched along with Opioid-Related Disorders in 12 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Opioid-Related Disorders: Disorders related to or resulting from abuse or misuse of OPIOIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 9.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 5.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| "Fluoxetine was not efficacious in reducing cocaine use in patients dually dependent on cocaine and opioids." | 2.76 | A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. ( Bigelow, GE; Johnson, RE; Silverman, K; Strain, EC; Winstanley, EL, 2011) |
| "Fluoxetine was examined as a candidate in two randomized, double-blind, placebo-controlled trials, one with cocaine-dependent patients (study 1) and the other with patients both cocaine and opiate dependent (study 2)." | 2.68 | Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. ( Creson, D; Davis, C; Elk, R; Grabowski, J; Kirby, K; Rhoades, H; Schmitz, J, 1995) |
| "Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats." | 1.33 | Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. ( Cador, M; Koob, GF; Stinus, L; Zorrilla, EP, 2005) |
| "Codeine is a substrate of CYP2D6, a genetically polymorphic P450 enzyme, and is metabolized to the more potent drug morphine." | 1.31 | Cytochrome P450 2D6 and treatment of codeine dependence. ( Otton, SV; Romach, MK; Sellers, EM; Somer, G; Tyndale, RF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Winstanley, EL | 1 |
| Bigelow, GE | 1 |
| Silverman, K | 1 |
| Johnson, RE | 2 |
| Strain, EC | 1 |
| Stinus, L | 1 |
| Cador, M | 1 |
| Zorrilla, EP | 1 |
| Koob, GF | 1 |
| Giroud, C | 1 |
| Michaud, K | 1 |
| Sporkert, F | 1 |
| Eap, C | 1 |
| Augsburger, M | 1 |
| Cardinal, P | 1 |
| Mangin, P | 1 |
| Polles, AG | 1 |
| Smith, PO | 1 |
| Grabowski, J | 2 |
| Rhoades, H | 1 |
| Elk, R | 2 |
| Schmitz, J | 1 |
| Davis, C | 1 |
| Creson, D | 2 |
| Kirby, K | 1 |
| Petrakis, I | 2 |
| Carroll, K | 1 |
| Gordon, L | 2 |
| Cushing, G | 1 |
| Rounsaville, B | 2 |
| Bertschy, G | 1 |
| Baumann, P | 1 |
| Batki, SL | 1 |
| Washburn, AM | 1 |
| Delucchi, K | 1 |
| Jones, RT | 1 |
| Schmitz, JM | 1 |
| Rhoades, HM | 1 |
| Hussein, I | 1 |
| Carroll, KM | 1 |
| Nich, C | 1 |
| Kosten, T | 1 |
| Romach, MK | 1 |
| Otton, SV | 1 |
| Somer, G | 1 |
| Tyndale, RF | 1 |
| Sellers, EM | 1 |
| Brooke, D | 1 |
| Fudala, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment With Lorcaserin for Cocaine Use: The TLC Study[NCT03192995] | Phase 2 | 22 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to FDA alert regarding study drug safety) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks
| Intervention | percent adherence (Mean) |
|---|---|
| Experimental | 51.6 |
| Control | 66.2 |
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks
| Intervention | mean percent of visit retention (Mean) | |
|---|---|---|
| Treatment Group | Control Group | |
| Mean Percent of Weekly Follow-up Visits by Treatment and Control Arms | 83 | 81 |
The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Proportion of self-reported weekly cocaine use by Time-Line-Follow-Up (TLFU) at baseline | Proportion of self-reported weekly cocaine use by TLFU at Week 12 | |
| Control | 6 | 6 |
| Experimental | 12 | 7 |
The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Urine positive samples with cocaine use at baseline | Urine positive samples with cocaine use at Week 12 | |
| Control | 0 | 1 |
| Treatment | 8 | 7 |
6 trials available for fluoxetine and Opioid-Related Disorders
| Article | Year |
|---|---|
A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.
Topics: Adult; Cocaine-Related Disorders; Double-Blind Method; Female; Fluoxetine; Humans; Male; Methadone; | 2011 |
Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials.
Topics: Adult; Cocaine; Demography; Double-Blind Method; Female; Fluoxetine; Humans; Male; Methadone; Opioid | 1995 |
A controlled trial of fluoxetine in crack cocaine dependence.
Topics: Adult; Ambulatory Care; Cocaine; Crack Cocaine; Double-Blind Method; Female; Fluoxetine; Humans; Mal | 1996 |
Medication take-home doses and contingency management.
Topics: Adult; Cocaine-Related Disorders; Female; Fluoxetine; Humans; Male; Methadone; Middle Aged; Opioid-R | 1998 |
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Cocaine; Cocaine-Related Disor | 1998 |
Weighing up the pros and cons: help-seeking by drug misusers in Baltimore, USA.
Topics: Adult; Bromocriptine; Buprenorphine; Cocaine; Desipramine; Fear; Female; Fluoxetine; Humans; Male; M | 1992 |
6 other studies available for fluoxetine and Opioid-Related Disorders
| Article | Year |
|---|---|
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learni | 2005 |
A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry(HILIC-MS).
Topics: Analgesics, Opioid; Biotransformation; Buprenorphine; Cannabinoids; Chromatography, Liquid; Cocaine; | 2004 |
Treatment of coexisting substance dependence and posttramatic stress disorder.
Topics: Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Fluoxetine; Humans; Ill | 1995 |
Fluoxetine treatment for dually diagnosed methadone maintained opioid addicts: a pilot study.
Topics: Adult; Cocaine; Combined Modality Therapy; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychi | 1994 |
Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Fluoxetine; Humans; Male; Meth | 1995 |
Cytochrome P450 2D6 and treatment of codeine dependence.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 | 2000 |